**­­BV-BRC SARS-CoV-2 Emerging Variant Report**

**August 9, 2022**

Details of the emerging variants analysis can be found in “BV-BRC SARS-CoV-2 Emerging Variant Report – 20220809.xlsx” based on sequence data from GISAID.

Keep in mind that the information provided reflects sequence counts and sequence proportions and, as such, is impacted by sampling bias in the sequence databases and should not be interpreted as the prevalence of disease caused by these variants.

In addition, due to sequence anomalies (e.g., ambiguous nucleotides in many sequence records) and other issues, the absolute counts of Variants of Concern sequences are likely to be underestimates of the true sequence prevalence.

***This report includes preliminary/incomplete stats for the month of August in order to identify early signs of novel variants emerging.***

The key findings are summarized below.

**USA – VOC**

**OMICRON**

* In the US, virtually all sequences reported to date in June, July, and August are **Omicron,** with **BA.2.12.1** displaced by **BA.5** and **BA.4** and their sub-lineages.
  + The CDC Nowcast for the week ending 08/06/22 estimates that **BA.5** proportions are now dominating in the United States at 87.1% (95% PI: 85.8-88.3%). Significant regional differences exist: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>.
  + The CDC Nowcast has split BA.4 and BA.4.6; estimates for **BA.4** proportions are now at 6.6% (95% PI: 6.1-7.2%); estimates for **BA.4.6** proportions are now at 4.8% (95% PI: 3.9-5.8%)
  + The US CDC Nowcast estimates that **BA.2.12.1** proportions are now at 1.5% (95% PI: 1.4-1.6%)
* A major re-organization of PANGO lineage nomenclature in mid-July impacted some of the earlier sequence prevalence data.
* Lineages with sequence prevalence >0.5% or ***growth rate >4*** in July are (ranked in order of sequence prevalence):
  + **BA.5.2.1** - 23%, 2.7 fold growth
  + **BA.2.12.1** - 11%, 0.25 fold growth
  + **BA.5.5** - 11%, 1.4 fold growth
  + **BA.5.1** - 10%, 3.0 fold growth
  + **BA.5.2** – 8.1%, 3.6 fold growth
  + **BA.4.1** – 6.8%, 1.1 fold growth
  + **BA.5.6** – 5.8%, 2.1 fold growth
  + **BA.5** – 3.9%, 3.0 fold growth
  + **BA.4** – 3.7%, 1.2 fold growth
  + **BA.4.6** – 2.7%, ***4.0 fold growth (carries R346T and N658S)***
  + **BA.5.1.1** – 2.0%, 1.9 fold growth
  + **BE.1** – 1.7%, 2.2 fold growth
  + **BE.3** – 1.6%, 1.9 fold growth
  + **BA.2** – 1.3%, 0.19 fold growth
  + **BE.1.1** – 1.0%, 4.0 fold growth
  + **BF.5** - 0.93%, 2.8 fold growth (carries A1020S)
  + **BA.5.1.2** - 0.21%, ***4.2 fold growth***
  + **BA.5.2.3** - 0.13%, ***4.3 fold growth***
  + **BE.2** - 0.09%, ***4.5 fold growth***
  + **BA.2.75** - 0.07%, ***7 fold growth***
  + **BF.3** - 0.06%, ***6 fold growth***
* ***In aggregate, BA.5.x sequences constitute 17% of sequences in June and 65% in July in the US***
* ***In aggregate, BA.4.x sequences constitute 5.8% of sequences in June and 14% in July in the US***
* Many sub-lineage variants appear to carry ancestral reversion in comparison to the original Omicron consensus, including inconsistent occurrence of A67V, H69-, V70-, G142D, V143-, Y144-, Y145-, N211-, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, N764K. However, these changes are likely due to sequencing artifacts caused by inefficient amplification by certain PCR primers affected by Omicron substitutions.
* Notable substitutions present within the top ten BA.5 sub-lineages in July so far in the US:
  + One **BA.5** sub-lineage (second most prevalent) carries the T76I substitution only
  + One **BA.5** sub-lineage carries the A701S substitution only
  + One **BA.5** sub-lineage carries the P1162L substitution only
  + One **BA.5** sub-lineage carries the L5F substitution only
* Notable substitutions present within the top ten BA.4 sub-lineages in July so far in the US:
  + Two **BA.4** sub-lineages (including the most prevalent) carry the V3G substitution only
  + One **BA.4** sub-lineage carries the N658S and R346T substitutions
  + One **BA.4** sub-lineage carries the N658S substitution only
  + One **BA.4** sub-lineage carries the V3G and I670V substitutions
  + One **BA.4** sub-lineage carries the N658S and A701V substitutions
  + One **BA.4** sub-lineage carries the V3G substitution and lacks the N440K substitution
  + One **BA.4** sub-lineage carries the N658S and D936N substitutions
  + One **BA.4** sub-lineage carries the V3G and R346T substitutions
* ***Several Omicron sub-lineages appear to carry a recurring mutation at position 346 in the S proteins (S:R346T in BA.2.74, BA.2.76, BA.4, BA.4.1, BA.4.6, BA.4.7, BA.5, BA.2.12.1, BA.2, S:R346S in BA.5.2.1or S:R346I in BA.4.1) and show growth rates > 1 fold from June and July***
* ***Clusters of BA.2 sub-lineage (BA.2.13, BA.2 56, BA.2.81) genomes from June and July carry the L452M substitution at the same position as L452Q, including the most prevalent BA.2 sublineage present at 8.4% in July***
* ***Several Omicron sub-lineages appear to carry a recurring mutation at position 444 in the S proteins (K444R in BA.5.2.1 with 5-fold growth rate, K444N in BA.5.2.1with 4-fold growth rate, and K444T in BA.5.6 with 3.5 fold growth rate in July)***
* ***BG.2 had 41 sequence in July in the US, and is similar to BA.4/5 except that it lacks the H69-,V70- deletion and the F486V substitution and contains the Q493R, S740L, and V1264L substitutions***

**DELTA** (**B.1.617.2** and **AY** sub-lineages) *(no significant change since previous report)*

* Two Delta sequences in the US in July.

**USA – (other VOCs and VOIs)** *(no significant change since previous report)*

* None in July.

**USA – Recombinants**

* **XE** – 6 sequences in the US in July
* **XM** – 1 sequence in the US in July
* **XAA** – 1 sequence in the US in July
* **XAC** – 1 sequence in the US in July
* See a summary of recombinant lineages at the end of this report.

**World – VOC**

**OMICRON**

* Omicron remains dominant globally, with the following lineages showing the highest sequence prevalence (> 0.5%) or growth rate (>3 fold) in July:
  + **BA.5.1** - 19%, 1.5 fold growth
  + **BA.5.2.1** - 18%, 2.3 fold growth
  + **BA.5.2** - 12%, 2.5 fold growth
  + **BA.2.12.1** – 5.6%, 0.27 fold growth
  + **BA.4.1** – 5.2%, 1.0 fold growth
  + **BA.5.5** – 4.4%, 1.4 fold growth
  + **BA.4** – 4.1%, 1.0 fold growth
  + **BA.5** – 3.5%, 1.7 fold growth
  + **BE.1.1** – 3.2%, 1.2 fold growth
  + **BF.5** – 3.0%, 3.1 fold growth
  + **BA.2** – 2.8%, 0.24 fold growth
  + **BA.5.6** – 2.7%, 2.1 fold growth
  + **BE.1** – 2.2%, 1.7 fold growth
  + **BA.4.6** – 1.6%, ***3.6 fold growth***
  + **BA.5.1.1** - 0.99%, 1.9 fold growth
  + **BF.1** - 0.75%, 0.94 fold growth
  + **BE.3** - 0.67%, 1.7 fold growth
  + **BA.5.3.1** - 0.59%, 1.3 fold growth
  + **BA.5.1.3** - 0.56%, 1.1 fold growth
  + **BA.5.2.**3 - 0.54%, 2.3 fold growth
* ***BA.2.75:*** *sometimes nicknamed “Centaurus”, this sublineage shows a high growth rate in India (129 fold in June and 3.7 fold in July), and is present in 21 other countries, including the United States (CA, IL, NY, NC, WA, WI, AZ, IA, VA). Preliminary signs of increasing growth rates for July in Australia, Austria, Japan, Nepal, US, Thailand, Indonesia, New Zealand, and Canada.*
* ***BA.2.76:*** *this sublineage showed a high growth rate globally in June (10 fold) but has slowed down in July (0.9 fold). Notable spike substituions in this variant include Y248N and R346T, both of which occur in antigenically important sites.*
* Similar issues with variable ancestral reversion that are likely due to sequencing artifacts, as described above for US sequences
* Notable substitutions present within the top ten **BA.5** sub-lineages globally in July:
  + One **BA.5** sub-lineage carries the T76I substitution
  + One **BA.5** sub-lineage lacks the R408S substitution
  + One **BA.5** sub-lineage lacks the N440K substitution
* Notable substitutions present within the top ten **BA.4** sub-lineages globally in July:
  + Two **BA.4** sub-lineages carry the V3G only
  + One **BA.4** sub-lineage carries the N658S substitution only
  + One **BA.4** sub-lineage carries the R346T and N658S substitutions (BA.4.6)
  + One **BA.4** sub-lineage carries the V3G and lacks the N440K substitution
  + One **BA.4** sub-lineage carries the V3G and I670V substitutions
  + One **BA.4** sub-lineage carries the V3G and lacks the R408S substitution
  + One **BA.4** sub-lineage carries the V3G and lacks the N440K and G142D substitutions
  + One **BA.4** sub-lineage carries the V3G and C1235F substitutions
* Substitutions in spike that we are monitoring (>3 fold growth from June to July) include the following (but note that the numbers are still relatively small for most of these):
  + **V70L** - 0.17%, 5.7 fold growth
  + **D1163Y** - 0.04%, 4 fold growth
  + **I68-** - 0.04%, 4 fold growth
  + **K444M** - 0.04%, 4 fold growth
  + **K444T** - 0.08%, 4 fold growth
  + **L24S** - 0.11%, 3.7 fold growth
  + **G339H** - 0.39%, 3.3 fold growth
  + **I210V** - 0.34%, 3.1 fold growth
  + **W152R** - 0.34%, 3.1 fold growth
  + **A1020S** – ***3.3%,*** 3 fold growth
  + **A67S** - 0.03%, 3 fold growth
  + **D1084E** - 0.03%, 3 fold growth
  + **E583D** - 0.03%, 3 fold growth
  + **G1099D** - 0.03%, 3 fold growth
  + **G1099S** - 0.03%, 3 fold growth
  + **G252D** - 0.03%, 3 fold growth
  + **K147I** - 0.03%, 3 fold growth
  + **N460K** - 0.39%, 3 fold growth
  + **Q218E** - 0.03%, 3 fold growth
  + **S221L** - 0.03%, 3 fold growth
  + **T1006I** - 0.03%, 3 fold growth
  + **T1116N** - 0.03%, 3 fold growth
  + **V193L** - 0.03%, 3 fold growth
  + **Y145H** - 0.03%, 3 fold growth

**DELTA** (**B.1.617.2** and **AY** sub-lineages)

* Thirteen Delta isolates globally in July
* Five (5) AY.45 like genomes have been detected in the Gauteng province of South Africa in June. These are part of a larger group of viruses (n=8) that appear to have features of both Delta and Omicron (BA.5). More information can be found on slide 19 of the [NGS-SA](https://www.nicd.ac.za/wp-content/uploads/2022/07/Update-of-SA-sequencing-data-from-GISAID-15-July-2022.pdf) report and on this github designation issue [here](https://github.com/cov-lineages/pango-designation/issues/844).

**World (other VOIs)**

* None in July

**World – Recombinants**

* **XAG** – 13 in July
* **XE** – 8 sequences in July
* **XAF** – 7 in July
* **XM** – 2 in July
* **XAA** – 1 in July
* **XAC** – 1 in July
* **XAE** – 1 in July
* See a summary of recombinant lineages at the end of this report.

**Variants that have been mentioned in the media and/or social media:**   
*On BA.2.75*

* [Virological characteristics of the SARS-CoV-2 Omicron BA.2.75](https://www.biorxiv.org/content/10.1101/2022.08.07.503115v1)
* Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
* [Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75](https://www.biorxiv.org/content/10.1101/2022.07.18.500332v2)
* [Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage](https://www.biorxiv.org/content/10.1101/2022.08.04.502609v1)
* [Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera](https://www.biorxiv.org/content/10.1101/2022.08.04.502716v1)
* [Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine](https://www.biorxiv.org/content/10.1101/2022.07.29.502055v2)
* [Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75](https://www.shionogi.com/global/en/news/2022/8/220810.html)

*Others*

* [Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5](https://www.biorxiv.org/content/10.1101/2022.08.02.502461v1)
* [Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination](https://www.nature.com/articles/s41467-022-32298-w)
* [Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection](https://www.nature.com/articles/s41467-022-32396-9)

**Recombinant lineages:**

Four new recombinant lineages have been designated this week (XAL and XAP). A summary table of previously identified recombinant lineages can be found below. We have added the number of recombinants genomes for each lineage. XA, XB, and XC have not been detected in the past 6 months. XD-XAP are Omicron or Omicron/Delta recombinants. The majority of these recombinant lineages do not appear to have taken off and several have not been detected in recent weeks. The XE lineage appears to have the largest number of genomes.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Github#** | **Lineage 1** | **Lineage 2** | **Location first detected** |
| **Name** | **number** |
| [XA](https://cov-lineages.org/lineage.html?lineage=XA) | 45 | NA | B.1.1.7 | B.1.177 | UK |
| [XB](https://cov-lineages.org/lineage.html?lineage=XB) | 3435 | [#189](https://github.com/cov-lineages/pango-designation/issues/189) | B.1.634 | B.1.631 | N. America |
| [XC](https://cov-lineages.org/lineage.html?lineage=XC) | 25 | [#263](https://github.com/cov-lineages/pango-designation/issues/263) | Delta (AY.29) | B.1.1.7 | Japan |
| [XD](https://cov-lineages.org/lineage.html?lineage=XD) | 28 | [#444](https://github.com/cov-lineages/pango-designation/issues/444) | Delta (AY.4) | BA.1 | France |
| [XE](https://cov-lineages.org/lineage.html?lineage=XE) | 2787 | [#454](https://github.com/cov-lineages/pango-designation/issues/454) | BA.1 | BA.2 | UK |
| [XF](https://cov-lineages.org/lineage.html?lineage=XF) | 34 | [#445](https://github.com/cov-lineages/pango-designation/issues/445) | Delta | BA.1 | UK |
| [XG](https://cov-lineages.org/lineage.html?lineage=XG) | 477 | [#447](https://github.com/cov-lineages/pango-designation/issues/447) | BA.1 | BA.2 | Denmark |
| [XH](https://cov-lineages.org/lineage.html?lineage=XH) | 174 | [#448](https://github.com/cov-lineages/pango-designation/issues/448) | BA.1 | BA.2 | Denmark |
| [XJ](https://cov-lineages.org/lineage.html?lineage=XJ) | 253 | [#449](https://github.com/cov-lineages/pango-designation/issues/449) | BA.1 | BA.2 | Finland |
| [XK](https://cov-lineages.org/lineage.html?lineage=XK) | 18 | [#460](https://github.com/cov-lineages/pango-designation/issues/460) | BA.1 | BA.2 | Belgium |
| [XL](https://cov-lineages.org/lineage.html?lineage=XL) | 119 | [#464](https://github.com/cov-lineages/pango-designation/issues/464) | BA.1 | BA.2 | UK |
| [XM](https://cov-lineages.org/lineage.html?lineage=XM) | 512 | [#472](https://github.com/cov-lineages/pango-designation/issues/472) | BA.1.1 | BA.2 | Multiple EU |
| [XN](https://cov-lineages.org/lineage.html?lineage=XN) | 158 | [#480](https://github.com/cov-lineages/pango-designation/issues/480) | BA.1 | BA.2 | UK |
| [XP](https://cov-lineages.org/lineage.html?lineage=XP) | 57 | [#481](https://github.com/cov-lineages/pango-designation/issues/481) | BA.1.1 | BA.2 | UK |
| [XQ](https://cov-lineages.org/lineage.html?lineage=XQ) | 142 | [#468](https://github.com/cov-lineages/pango-designation/issues/468) | BA.1.1 | BA.2 | UK |
| [XR](https://cov-lineages.org/lineage.html?lineage=XR) | 181 | [#469](https://github.com/cov-lineages/pango-designation/issues/469) | BA.1.1 | BA.2 | UK |
| [XS](https://cov-lineages.org/lineage.html?lineage=XS) | 59 | [#471](https://github.com/cov-lineages/pango-designation/issues/471) | Delta | BA.1.1 | USA |
| [XT](https://cov-lineages.org/lineage.html?lineage=XT) | 13 | [#478](https://github.com/cov-lineages/pango-designation/issues/478) | BA.2 | BA.1\* | S. Africa |
| [XU](https://cov-lineages.org/lineage.html?lineage=XU) | 17 | [#522](https://github.com/cov-lineages/pango-designation/issues/522) | BA.1\* | BA.2 | India |
| [XV](https://github.com/cov-lineages/pango-designation/issues/463) | 42 | [#463](https://github.com/cov-lineages/pango-designation/issues/463) | BA.1\* | BA.2\* | Denmark |
| [XW](https://github.com/cov-lineages/pango-designation/issues/591) | 99 | [#591](https://github.com/cov-lineages/pango-designation/issues/591) | BA.1\* | BA.2\* | JP, DE, SI, CA, UK, US |
| [XY](https://github.com/cov-lineages/pango-designation/issues/606) | 118 | [#606](https://github.com/cov-lineages/pango-designation/issues/606) | BA.1\* | BA.2\* | FR, IL, UK, US |
| [XZ](https://github.com/cov-lineages/pango-designation/issues/636) | 106 | [#636](https://github.com/cov-lineages/pango-designation/issues/636) | BA.2\* | BA.1\* | Multiple |
| XAA | 96 | [#664](https://github.com/cov-lineages/pango-designation/issues/664) | BA.1\* | BA.2\* | US, IL |
| XAB | 112 | #[665](https://github.com/cov-lineages/pango-designation/issues/665) | BA.1\* | BA.2\* | IT, FR, DE, CH, DK |
| XAC | 204 | #[590](https://github.com/cov-lineages/pango-designation/issues/590) | BA.1\* | BA.2\* | IL, DE, CA, IR, NL, JP, UK, US |
| XAD | 54 | [#607](https://github.com/cov-lineages/pango-designation/issues/607) | BA.2\* | BA.1\* | CZ,DE,UK |
| XAE | 128 | [#637](https://github.com/cov-lineages/pango-designation/issues/637) | BA.2\* | BA.1\* | CA,US,NL,CH |
| XAF | 260 | [#676](https://github.com/cov-lineages/pango-designation/issues/676) | BA.1\* | BA.2\* | CR |
| XAG | 347 | [#709](https://github.com/cov-lineages/pango-designation/issues/709) | BA.1.1 | BA.2.23 | BR |
| XAH | 82 | [#755](https://github.com/cov-lineages/pango-designation/issues/755) | BA.2\* | BA.1\* | SI |
| XAJ | 35 | [#826](https://github.com/cov-lineages/pango-designation/issues/826) | BA.2.12.1 | BA.4 | UK |
| XAK | 55 | [#823](https://github.com/cov-lineages/pango-designation/issues/823) | BA.1\* | BA.2\* | DE |
| XAL | 95 | [#757](https://github.com/cov-lineages/pango-designation/issues/757) | BA.1.1 | BA.2\* | DE |
| XAM | 341 | [#759](https://github.com/cov-lineages/pango-designation/issues/759) | BA.1.1 | BA.2.9 | Panama |
| XAN | 35 | [#771](https://github.com/cov-lineages/pango-designation/issues/771) | BA.2\* | BA.5.1 | Multiple |
| XAP | 69 | [#789](https://github.com/cov-lineages/pango-designation/issues/789) | BA.2\* | BA.1\* | US |

**Newly designated Pango lineages:**

Not many new lineages designated this week, however there are several proposed ne lineages with important characteristics that should be monitored.

* **BH.1**: BA.2.38.3 sublineage with S:144del, S:446S, S:452Q, Orf1a:A3357G and Orf1a:F1214I emerging in India
* [BA.2.10 (.1) sublineage with S:V83A, H146Q, Q183E, V213E, G339H, R346T, L368I, V445P, G446S, V483A, F490V, G798D, S1003I (India)](https://github.com/cov-lineages/pango-designation/issues/915)
* [BA.2.10 sublineage with S:W64R, 141-144del, 243-244del, G446S, F486P, R493Q, S494P, P1143L (India)](https://github.com/cov-lineages/pango-designation/issues/898)
* [BA.5.2 sublineage with S:K444M (Europe)](https://github.com/cov-lineages/pango-designation/issues/924)
* [Sublineage of BE.1 with S:R346T(Costa Rica & USA)](https://github.com/cov-lineages/pango-designation/issues/923)
* [Sublineage of BA.5.6 with S:K444T](https://github.com/cov-lineages/pango-designation/issues/903)

**Variants being monitored by various public health agencies:**

The ECDC has added the Omicron sublineage BA.2.75 to its list of “[Variants of](https://www.ecdc.europa.eu/en/covid-19/variants-concern) Interest” list.

The latest summary table for all agencies can be found here:

[https://docs.google.com/spreadsheets/d/1mAgO2wRJyEyGtL-SBe3NgOjUk7a5nZTeKmSorVkaHSU/edit#gid=0](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdocs.google.com%2Fspreadsheets%2Fd%2F1mAgO2wRJyEyGtL-SBe3NgOjUk7a5nZTeKmSorVkaHSU%2Fedit%23gid%3D0&data=04%7C01%7Caniewiad%40jcvi.org%7Ca70439f28bea4eef8a1e08d97defe970%7C24d967f13ed84448baa6560ec572acb3%7C0%7C0%7C637679291653602250%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=nt2Bhicg1KDdY%2F2YTTzcFc2y4VEHbDdYFzNY6%2Fi0BRE%3D&reserved=0)